Experimental CAR-T therapy targets Hard-to-Treat brain autoimmune diseases
NCT ID NCT07341828
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new treatment called C-CAR168, which uses a patient's own immune cells modified to attack harmful cells in the body. It is for 15 adults with multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person syndrome that have not improved with standard treatments. The main goal is to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
C-CAR168 (a type of CAR-T cell therapy that targets CD20 and BCMA proteins)
What this could lead to
If it works, this could point toward a new treatment option for people with severe central nervous system autoimmune diseases that haven't responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 15 people, focused mainly on safety. It may not show clear benefit, and CAR-T therapy carries risks like cytokine release syndrome and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STIFF PERSON SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••